Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
CLINUVEL PHARMS LTD S/ADR (CLVLY)
NASDAQ:AMEX Investor Relations:
clinuvel.com/investors
Company Research
Source: GlobeNewswire
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf. Managing Director and CEO, Dr Philippe Wolgen shared the Company’s success in establishing profitability over the past seven financial years, building a strong balance sheet, commercialising the innovative melanocortin drug SCENESSE®, and plans to bring melanocortin technology to wider audiences with unmet needs. CLINUVEL is now investing heavily in R&D with an ambitious clinical pipeline, including a phase III clinical trial for the pigment loss disorder vitiligo. A case study presented at the American Academy of Dermatology Meeting on 9 March highlighted the systemic repigmentation of the skin of a female patient from the
Show less
Read more
Impact Snapshot
Event Time:
CLVLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLVLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLVLY alerts
High impacting CLINUVEL PHARMS LTD S/ADR news events
Weekly update
A roundup of the hottest topics
CLVLY
News
- Is Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? [Yahoo! Finance]Yahoo! Finance
- Clinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 50% loss from investing in the stock three years ago [Yahoo! Finance]Yahoo! Finance
- Malibu shines a light on CLINUVEL’s pioneering work in photomedicineGlobeNewswire